Letter from Pew: Updates on the Unique Device Identifier System
A letter from Josh Rising, director of Pew's Medical Device Initiative, about updates on the unique device identifier system.
More info"WASHINGTON – The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with industry released by the agency on Friday.
...
'These agreements are important because they are a substantial resource that lets the agency carry out its mission of protecting patients and ensuring important products come to market in a timely way,' said Allan Coukell, director of the Pew Charitable Trusts' health advocacy group. 'For the first time we will also have funding directed at increasing FDA's inspection of foreign manufacturing facilities.'... "
Full Article- Date added:
- Jan 13, 2012
- Projects:
- Drug Safety Project, Innovate FDA
- Topics:
- Drug Safety, Drugs and Devices at the FDA
- Related Expert:
- Allan Coukell
Related Resources
Pew Comment Letter to the Senate HELP Committee on Compounding Legislation
Pew sent a comment letter to the Senate Committee on Health, Education, Labor and Pensions on the Pharmaceutical Compounding Quality and Accountability Act. This bill takes steps toward clarifying state and federal oversight of compounding, including an important increase in FDA supervision of certain activities—specifically, the compounding of sterile medicines that are shipped interstate.
More infoLetter from Pew to FDA on Postmarket Surveillance Plan
FDA recently updated the national medical device postmarket surveillance plan – listing device identification and registries as the cornerstones for effective product monitoring. In this letter, medical devices director Josh Rising applauds the agency for making unique device identifiers and registries central to this plan.More info
''Lawmaker Would Give FDA More Oversight of Drug Compounding''
Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug compounding.
More infoPew Testimony: Examining Drug Compounding
On Thursday, May 23, the House Energy & Commerce Subcommittee on Health held a hearing, entitled "Examining Drug Compounding." Gabrielle Cosel, a drug safety expert, testified on the need to clarify oversight of compounding pharmacies on the state and federal level.
More info
''Senate Panel Approves Tighter Oversight of Compounding Pharmacies, but Bill is Under Fire''
Public health and consumer advocacy groups are attacking Senate legislation designed to tighten oversight of specialized pharmacies such as the one at the center of this past fall’s deadly meningitis outbreak, saying it does not adequately address health risks.
More info''Rep. Bob Latta's Plan to Thwart Fake Drugs Passes House of Representatives Committee''
An Ohio legislator’s plan to establish a nationwide prescription drug tracking system to protect patients from fake drugs was approved by the House Commerce Committee. More info''Drug Manufacturer Agrees to $500 Million Penalty''
''A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S."
More info''Community Pharmacies Will Now Back Supply Chain Legislation''
"As differing bills for securing the pharmaceutical supply chain wind their way through the US House and Senate, a key hurdle to passing legislation may have just been cleared. Earlier this week, the National Community Pharmacists Association – which is a member of an influential industry coalition that has been floating its own proposals – is now willing to back either bill."
More info''Senators Say They Are Close to Writing a Final Pharmacy Compounding Bill''
"U.S. senators considering fundamental changes to how the practice of pharmacy compounding is regulated heard almost unanimous support for reform at a Washington committee hearing Thursday."
More info''Senate Moves Closer to Law to Prevent More Pharmacy Outbreaks''
"At least 67 people have died in 20 outbreaks caused by contaminated drugs since 2001, experts told a Senate hearing Thursday. The Food and Drug Administration says there have likely been more cases than that, but they have no way of telling now."
More info''State Pharmacy Boards Back More FDA Oversight''
"State pharmacy officials on Thursday threw their support behind a proposal giving the Food and Drug Administration authority over large compounding pharmacies, in an effort to head off more outbreaks tied to contaminated medications."
More infoPew Testimony on the Safety of Compounding Pharmacies
The U.S. Senate Committee on Health, Education, Labor and Pensions held a hearing on May 9 entitled "Pharmaceutical Compounding: Proposed Legislative Solution." Pew's Allan Coukell, a pharmacist and drug safety expert, testified on the need to strengthen oversight of the compounding industry.
More info''The Senate Aims to Clean Up Compounding Pharmacies''
When a doctor sticks a needle in you, you expect that the drugs it carries won’t be tainted. But, possibly owing to a strange gray area in federal law, thousands of patients last October got injections for back pain that contained highly dangerous fungal meningitis, and dozens of them died. Members of the Senate Health, Education, Labor and Pensions Committee are now seeking to fix the government’s oversight of the obscure world of compounding pharmacies. The reforms they want are overdue.
More infoPew Comments to Senate HELP Committee on Drug Distribution Security
The Pew Charitable Trusts commented on the draft proposal to secure drug distribution in the United States. Although recognizing that the draft is the product of a sustained effort to address a complex system and balance sometimes competing imperatives, Pew shared areas of significant concern.
More info
